Halozyme Therapeutics, Inc. (HALO) Financials
HALO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 2.7 billion | 2.5 billion |
| Dec. 31, 2025 | 2.5 billion | 2.5 billion |
| Sept. 30, 2025 | 2.2 billion | 1.7 billion |
| June 30, 2025 | 2.1 billion | 1.7 billion |
HALO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 176.3 million | 16.6 million |
| Dec. 31, 2025 | 217.6 million | 16.6 million |
| Sept. 30, 2025 | 175.6 million | 12.2 million |
| June 30, 2025 | 98.1 million | 12.2 million |
HALO Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| March 31, 2026 | 150.0 million |
| Dec. 31, 2025 | -141.6 million |
| Sept. 30, 2025 | 175.2 million |
| June 30, 2025 | 165.2 million |
HALO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 318.6 million | - | - |
| Dec. 31, 2025 | 142.8 million | - | - |
| Sept. 30, 2025 | 702.0 million | 800.1 million | - |
| June 30, 2025 | 548.2 million | 1.5 billion | - |
HALO Shares Outstanding
HALO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 3.7 million | 25.6 million | 57.9 million | - |
| Dec. 31, 2025 | 1.4 million | 31.9 million | 63.3 million | - |
| Sept. 30, 2025 | 3.0 million | 17.3 million | 46.1 million | - |
| June 30, 2025 | 1.6 million | 17.5 million | 41.6 million | - |
HALO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 376.7 million | 108.8 million |
| Dec. 31, 2025 | 451.8 million | 102.1 million |
| Sept. 30, 2025 | 354.3 million | 73.0 million |
| June 30, 2025 | 325.7 million | 64.1 million |
HALO Revenue by Segment
Graph available only for paid members. Upgrade to see it.
HALO
Price: $70.90
52 week price:
Payout Ratio Range:
Earnings Per Share: 2.85 USD
P/E Ratio: 23.55
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 402302
Ebitda: 127.5 millionMarket Capitalization: 8.5 billion